David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
|Videos|October 4, 2017
Dr. Patel Discusses Checkpoint Blockade in NSCLC
Author(s)Jyoti Patel, MD
Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer.
Advertisement
Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non—small cell lung cancer (NSCLC).
There have been significant responses to checkpoint blockades, but only about 20% of patients demonstrate response.
The goal now is to bring the right immunotherapy agents to a broader population, says Patel, giving more patients a chance at response.
Advertisement
Related to this article
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
2
IDMC Recommends Continuation of Phase 2 MRD Study of IMNN-001 in Advanced Ovarian Cancer
3
Dr Mayer on the FDA Approval of Camizestrant for ESR1-Mutated Breast Cancer
4
INCB161734 Holds Potential Significance for KRAS G12D–Mutated mPDAC Management
5